<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6624">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02010203</url>
  </required_header>
  <id_info>
    <org_study_id>HS410-101</org_study_id>
    <nct_id>NCT02010203</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of HS-410 in Patients With High-Risk Non-Muscle Invasive Bladder Cancer After TURBT and BCG</brief_title>
  <official_title>A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With High-Risk Non-Muscle Invasive Bladder Cancer Who Have Undergone TURBT and Received Prior Treatment With Induction BCG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heat Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heat Biologics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part study.  The first stage will test the safety of HS-410 and the second
      stage will determine whether vaccination with HS-410 after transurethral resection of
      bladder tumor (TURBT) and bacillus Calmette-Guérin (BCG) extends the time to disease
      recurrence compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase 1: Immune response</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunologic response via intracellular cytokine staining (ICS) by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) on CD8+ cells after receiving 6 vaccine doses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Time to Recurrence</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor antigen expression analysis</measure>
    <time_frame>At screening</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of pre-treatment tumor tissue for antigen expression</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor Infiltrating Lymphocytes (TILs)</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of post-treatment tumor tissue for the presence of infiltrating T-cells</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>HS-410 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-410 given as 1*10^6 cells for 12 weekly injections followed by 3 monthly injections open label in Phase 1 portion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-410 High-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-410 given as 1*10^7 cells for 12 weekly injections followed by 3 monthly injections open label in the Phase 1 portion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-410 Phase 2 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal dose of HS-410 from Phase 1 given as 12 weekly injections followed by 3 monthly injections randomized double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given as 12 weekly injections followed by 3 monthly injections randomized double-blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-410</intervention_name>
    <description>Vaccine derived from irradiated urothelial bladder cancer cells genetically engineered to continually secrete gp96</description>
    <arm_group_label>HS-410 Low Dose</arm_group_label>
    <arm_group_label>HS-410 High-Dose</arm_group_label>
    <arm_group_label>HS-410 Phase 2 dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection containing sterile solution but no cells</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed or recurrent high grade non-muscle invasive bladder cancer with or
             without carcinoma in situ that has been removed by transurethral resection

          -  Received 3-6 weekly doses of intravesical bacillus Calmette-Guérin (BCG) in the
             adjuvant setting

          -  Adequate laboratory parameters

          -  Bladder cancer risk assessment score &gt;=8 on the recurrence scale and &lt;=18 on the
             progression scale

        Exclusion Criteria:

          -  Prior immunologic or biologic response modifier therapy for treatment of this
             occurrence

          -  Recurrence &lt;12 months from most recent prior transurethral resection of bladder tumor
             (TURBT)

          -  Prior immunologic, biologic response modifier, chemotherapy, radiation, or  therapy
             for treatment of this occurrence

          -  Intercurrent autoimmunity or immunodeficiency syndromes

          -  Significant cardiac impairment

          -  Other malignancies within the last 3 years

          -  Known allergy to soy or egg products
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Steinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Price, PhD</last_name>
    <phone>919-240-7133</phone>
    <email>mprice@heatbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Kelley</last_name>
    <phone>919-240-7133</phone>
    <email>jkelley@heatbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Gibson</last_name>
      <phone>303-421-5783</phone>
      <email>jgibson@tucc.com</email>
    </contact>
    <investigator>
      <last_name>Larry Karsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MaryAnn Schroder</last_name>
      <phone>773-834-9198</phone>
      <email>mschroder@surgery.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Steinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Urology</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Dallas</last_name>
      <phone>812-288-2611</phone>
      <email>cdallas@1sturology.com</email>
    </contact>
    <investigator>
      <last_name>James Bailen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapell Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madeline Carroll</last_name>
      <phone>919-843-5199</phone>
      <email>madeline_carroll@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Woods, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Allen</last_name>
      <phone>843-449-1010</phone>
      <phone_ext>265</phone_ext>
    </contact>
    <investigator>
      <last_name>Neal Shore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>December 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TURBT</keyword>
  <keyword>Bladder</keyword>
  <keyword>Cancer</keyword>
  <keyword>GP96</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Heat Biologics</keyword>
  <keyword>BCG</keyword>
  <keyword>Bacillus Calmette-Guerin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
